Back to Search
Start Over
Efficacy and safety of Brolucizumab for neovascular age-related macular degeneration: a systematic review and meta-analysis.
- Source :
-
PeerJ [PeerJ] 2024 Jun 21; Vol. 12, pp. e17561. Date of Electronic Publication: 2024 Jun 21 (Print Publication: 2024). - Publication Year :
- 2024
-
Abstract
- Background: To evaluate the efficacy and safety of Brolucizumab for neovascular age-related macular degeneration (n-AMD) through a systematic review and meta-analysis.<br />Materials and Methods: Cochrane, PubMed, Embase, and Web of Science databases were comprehensively searched for relevant studies. Stata and RevMan5.4 were applied for meta-analysis and risk of bias assessment. Data on the best-corrected visual acuity (BCVA), central subfield thickness (CSFT), presence of intraretinal fluid (IRF) and/or subretinal fluid (SRF), participants with ≥1 serious adverse events, and participants with ≥1 adverse events were analyzed.<br />Results: Six studies were finally included. Meta-analysis showed statistical differences in BCVA [SMD = -0.65, 95% CI [-0.17 to -0.23], P < 0.05], the presence of IRF and/or SRF [RR = 0.67, 95% CI [0.56-0.79], P < 0.05], and the safety of participants with ≥1 serious adverse events [RR = 0.57, 95% CI [0.39-0.84], P < 0.05] between the experimental group and the control group. However, no statistical differences were observed in CSFT [SMD = -1.16, 95% CI [-2.79 to 0.47], P > 0.05] or the safety of participants with ≥1 adverse events [RR = 1.07, 95% CI [0.97-1.17], P > 0.05].<br />Conclusions: Compared to other anti-VEGF drugs such as Aflibercept and Ranibizumab, intravitreal injection of 6 mg Brolucizumab is more effective and safer for n-AMD, especially in the presence of IRF and/or SRF, and for participants with ≥1 serious adverse events.<br />Competing Interests: The authors declare that they have no competing interests.<br /> (© 2024 Dou and Jiang.)
- Subjects :
- Humans
Intravitreal Injections
Treatment Outcome
Visual Acuity drug effects
Wet Macular Degeneration drug therapy
Angiogenesis Inhibitors adverse effects
Angiogenesis Inhibitors therapeutic use
Antibodies, Monoclonal, Humanized therapeutic use
Antibodies, Monoclonal, Humanized adverse effects
Macular Degeneration drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 2167-8359
- Volume :
- 12
- Database :
- MEDLINE
- Journal :
- PeerJ
- Publication Type :
- Academic Journal
- Accession number :
- 38915383
- Full Text :
- https://doi.org/10.7717/peerj.17561